This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Progesterone and Second Trimester Bleeding

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2016 by Raed Salim, HaEmek Medical Center, Israel
Information provided by (Responsible Party):
Raed Salim, HaEmek Medical Center, Israel Identifier:
First received: January 3, 2011
Last updated: September 1, 2016
Last verified: September 2016

Working hypothesis and aims:

To investigate whether progesterone treatment affects the incidence of preterm labor compared to placebo, among women with 2nd trimester bleeding.

The participants will be allocated through randomization to a study or control group. Women in the study group will receive micronized progesterone 200 mg (Utrogestan, company) with an intra-vaginal tablet once daily while the control group will receive placebo. Both women and medical staff will be blinded to group allocation. Treatment will commence on the day of inclusion to the study, but not before 16 weeks and will continue until 36 weeks gestation. Data will be collected after the conclusion of pregnancy regarding the maternal and neonatal outcome.

Condition Intervention
Antepartum Bleeding Preterm Birth Drug: micronized progesterone 200 mg (Utrogestan) Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Impact of Progesterone on the Risk of Preterm Birth Among Women With Second Trimester Bleeding. A Double Blind Placebo Controlled Trial

Resource links provided by NLM:

Further study details as provided by Raed Salim, HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Incidence of spontaneous preterm birth - before 37 weeks. [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Maternal and fetal outcomes [ Time Frame: 3 years ]

Estimated Enrollment: 268
Study Start Date: December 2010
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Utrogestan Drug: micronized progesterone 200 mg (Utrogestan)
micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
Placebo Comparator: placebo Drug: placebo
placebo 200mg vaginal tablets


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Viable pregnancy
  • Gestational age between 13 to 26 weeks
  • Vaginal bleeding from uterine origin
  • Singleton pregnancy
  • Normal clotting tests
  • Hemodynamically stable woman

Exclusion Criteria:

  • Water leak
  • Signs of preterm labor
  • Fetal malformations incompatible with life
  • Uterine malformations and other maternal conditions, i.e. liver disease, breast cancer, active thromboembolic state
  • Past preterm birth
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01269450

Contact: RAED SALIM, MD 97246494355
Contact: GALI GARMI, MD 97246494355

Emek medical center Recruiting
Afula, Israel, 18101
Contact: Raed Salim, MD    97246494031   
Principal Investigator: Manal Massalha, MD         
dEP ob/gyn, Hillel Yaffe Medical Center. Recruiting
Hadera, Israel
Contact: Ilan Bruchim, MD   
Dep. OB/GYN, The Nazareth Hospital, E.M.M.S Recruiting
Nazareth, Israel
Contact: Marwan Hakim, MD   
Principal Investigator: Marwan Hakim, MD         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Principal Investigator: RAED SALIM, MD HaEmek medical center affiliated to the Rappaport faculty of medicine, Technion, Haifa, Israel
  More Information

Additional Information:
Responsible Party: Raed Salim, Dr., HaEmek Medical Center, Israel Identifier: NCT01269450     History of Changes
Other Study ID Numbers: 0023-08-EMC
Study First Received: January 3, 2011
Last Updated: September 1, 2016

Keywords provided by Raed Salim, HaEmek Medical Center, Israel:
second trimester vaginal bleeding
late abortion
preterm birth

Additional relevant MeSH terms:
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Pathologic Processes
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 19, 2017